452 related articles for article (PubMed ID: 30255103)
1. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy.
Liu P; Chen L; Zhang H
J Immunol Res; 2018; 2018():1206737. PubMed ID: 30255103
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
3. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
5. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.
Sun C; Sun H; Zhang C; Tian Z
Cell Mol Immunol; 2015 May; 12(3):292-302. PubMed ID: 25308752
[TBL] [Abstract][Full Text] [Related]
6. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
7. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma.
Nishida S; Levi DM; Tzakis AG
Curr Opin Organ Transplant; 2013 Dec; 18(6):690-4. PubMed ID: 24220052
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.
Yu M; Li Z
Front Med; 2017 Dec; 11(4):509-521. PubMed ID: 28780700
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
10. T-cell-associated immunotherapy: a promising strategy for the treatment of hepatocellular carcinoma.
Ma W; Chen X; Yuan Y
Immunotherapy; 2017 Jun; 9(7):523-525. PubMed ID: 28595519
[No Abstract] [Full Text] [Related]
11. Kbtbd2 inhibits the cytotoxic activity of immortalized NK cells through down-regulating mTOR signaling in a mouse hepatocellular carcinoma model.
Dai K; Huang Y; Chen Z; Sun X; Yang L; Jiang Y
Eur J Immunol; 2018 Apr; 48(4):683-695. PubMed ID: 29331106
[TBL] [Abstract][Full Text] [Related]
12. NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma.
Sui Q; Zhang J; Sun X; Zhang C; Han Q; Tian Z
J Immunol; 2014 Aug; 193(4):2016-23. PubMed ID: 25015826
[TBL] [Abstract][Full Text] [Related]
13. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
Barrow AD; Colonna M
Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
[TBL] [Abstract][Full Text] [Related]
14. NK cells in hepatitis B virus infection: a potent target for immunotherapy.
Shabani Z; Bagheri M; Zare-Bidaki M; Hassanshahi G; Arababadi MK; Mohammadi Nejad M; Kennedy D
Arch Virol; 2014 Jul; 159(7):1555-65. PubMed ID: 24445811
[TBL] [Abstract][Full Text] [Related]
15. Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model.
Chen M; Xu M; Zhu C; Wang H; Zhao Q; Zhou F
Cancer Immunol Immunother; 2019 Jun; 68(6):961-971. PubMed ID: 30955067
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
17. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
Shin S; Kim M; Lee SJ; Park KS; Lee CH
Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
[TBL] [Abstract][Full Text] [Related]
18. Perspectives of immunotherapy in hepatocellular carcinoma (HCC).
Büttner N; Schmidt N; Thimme R
Z Gastroenterol; 2016 Dec; 54(12):1334-1342. PubMed ID: 27936483
[TBL] [Abstract][Full Text] [Related]
19. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.
Hirofuji H; Kakumu S; Fuji A; Ohtani Y; Murase K; Tahara H
Clin Exp Immunol; 1987 May; 68(2):348-56. PubMed ID: 2820634
[TBL] [Abstract][Full Text] [Related]
20. STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.
Han Q; Wang Y; Pang M; Zhang J
J Exp Clin Cancer Res; 2017 Nov; 36(1):156. PubMed ID: 29115974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
